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MOST STUDIES of the prognostic significance of premature ventricular complexes (PVCs) have emphasized the importance of the "complex" features and frequency of the PVCs in determining prognosis.'~" Complex features include multifocality, presence of two (couplets) or more (runs) consecutive PVCs and the R-on-T phenomenon. Elimination of the specific "4malignant forms" with or without reduction of overall PVC rates may be a reasonable goal of therapy designed to protect against symptomatic ventricular tachycardia or sudden death.`However, previous evaluations of the effectiveness of antiarrhythmic agents have usually focused simply on the total number of PVCs. An accurate measurement of the effects of antiarrhythmic agents on specific forms of ventricular ectopic beats could not be performed because of limitations of standard Holter analysis techniques.
The Argus/H computerized Holter analysis system allows enumeration of PVCs, couplets and runs subgrouped by coupling intervals. 7 In this study, we used this analytic capability to evaluate the therapeutic activity of phenytoin, quinidine and procainamide against these complex PVCs.
Methods
Thirteen patients (11 men and two women) who had multifocal PVCs, couplets or runs and who had an average PVC rate of over 50/hour on each of two qualifying 10-hour ambulatory Holter recordings were enrolled in this study. All patients had coronary heart disease, and all had survived one or more myocardial infarctions 3-35 months before the study. Two patients had undergone coronary bypass surgery 6 and 11 months previously. The patients ranged in age from 50-70 years. No patient had hepatic or renal disease, uncompensated heart failure or atrioventricular block. Seven patients continued taking digoxin; serum levels were measured and dosage was initially adjusted to maintain a level of 1-2 ng/ml. Serum potassium was measured weekly and maintained at greater than 3.5 mEq/l. Patient 1 had been taking 20 mg of propranolol four times a day for control of angina before the study, and continued this regimen through-out the study. All patients and their personal physicians were informed of the purpose of the study and each patient gave written informed consent. Relevant patient characteristics are presented in table 1.
The drugs and dosages used in this study reflect current medical practice. To simplify the double-blind format, no attempt was made to regulate dosage according to measured drug levels. Quinidine was administered four times a day at 300 mg, procainamide at 500 mg four times a day, phenytoin at 100 mg four times a day and placebo four times a day. All drugs and placebo were packaged in identical-appearing capsules and were administered for 7 days, with the order of drug administration randomized within groups of four. A loading dose of 500 mg was given at the start of the phenytoin trial. No other loading doses were used, but patients received a standard dose with four identical placebo capsules at the start of the other drug trials to maintain the blinding.
A 24-hour, single-channel Holter recording was obtained on the seventh day of drug administration and a serum drug level was obtained when the recording was begun. No attempt was made to standardize the time the serum level was obtained. Each patient kept a diary for the complete 7 days of drug administration. They also completed a questionnaire about side effects at the time of the Holter recording. All unused capsules were collected and counted to monitor compliance. If reported side effects required, the particular drug was discontinued and the next drug initiated at the originally scheduled time. Patient 3 had only one 10-hour recording during the placebo period, so only 10-hour results were tabulated for him. Patient 4 had only one 10-hour recording during the quinidine drug trial, so the results for quinidine were compared with the first 10 hours of the placebo tape.
The Holter tapes were processed and analyzed by the Argus/H computer system. In brief, the analog tape was digitized and processed by a cascading series of data-reduction algorithms.7 8 Each computeridentified PVC was then presented to a trained editor, who examined it within 16 seconds of context and confirmed or denied the computer label. Representative strips documenting the editing decisions were produced and subsequently reviewed by a cardiologist. The annotated ECG in the form of a machinereadable beat-by-beat data stream was then passed as input to a program that reduced that data stream to 150 variables of interest.9 Subsequent data management and statistical analyses were performed using the SAS system. 10 The following variables were chosen for analysis. Average heart rate was based on the average coupling interval between consecutive normal beats. A couplet was defined as two consecutive PVCs and a run as three or more consecutive PVCs. An isolated PVC was a PVC preceded and followed by a non-PVC beat. The coupling interval of the PVC was the time in milliseconds from the onset of the QRS preceding the PVC to the onset of the PVC. Coupling intervals of PVCs within couplets or runs included only PVC-to-PVC intervals within the couplets or runs. The rate of runs was calculated from the average PVC-to-PVC coupling interval within the run. The PVC rates per hour were calculated and corrected for data loss when the signal was unanalyzable. Because the range of PVC rates was wide and not normally distributed, a log transform was used for all statistical analyses. This resulted in more nearly normal distributions and served to control severe heterogeneity of the variance. For clarity of presentation, the mean PVC rates were converted back to natural units as PVCs/hour. Comparison between placebo and drug was performed using a paired t test. A p value < 0.05 was considered significant.
Results
Twelve patients satisfactorily completed the study. Patient 13, who was in compensated congestive heart failure at the onset of the trial, developed pulmonary edema during the trial and was excluded from the analysis. Patients 5 and 10 had fewer than three PVCs/hour during the placebo period and were excluded from further analysis. The other 10 patients successfully completed the trials of quinidine and procainamide. Patients 7, 9 and 11 discontinued phenytoin because of severe side effects -allergic rash and pruritis in two and severe weakness and muscle aches in the other. All of the symptoms resolved rapidly after discontinuation of the phenytoin and the patients continued the study at the end of the week with the next drug. Side effects not severe enough to Procainamide reduced the numbers of PVCs in couplets and runs with PVC-to-PVC coupling intervals (V-V) of less than 400 msec, (p < 0.02) and also reduced couplets with V-V of 400-500 msec (p < 0.05, table 5). Figure 1 shows the relative reduction of PVCs with shorter V-V coupling intervals. Patients who took procainamide had fewer runs than those who took placebo, but this difference did not reach statistical significance. Couplets with a rate faster than 100/minute (V-V < 600 msec), however, were significantly reduced (p < 0.02). Couplets with a longer coupling interval were also reduced but the reduction was not statistically significant.
Effect of Quinidine
All 10 patients completed the study, although one complained of severe diarrhea and another of gastric distress, which ultimately might have caused discontinuation of the drug. Two patients had serum levels lower than 2 ,ug/ml, but statistical analysis was carried out on all 10 patients. Four patients had a greater than 90% reduction in PVCs. Overall, patients who took quinidine had fewer PVCs than those who took placebo, but the results did not reach statistical significance (p > 0.09). The number of couplets with V-V intervals less than 600 msec was reduced (p < 0.05) and the number of runs with V-V intervals less than 600 msec was also reduced slightly, but the numbers are smaller and not significant (table 4). 1The analysis for this patient was based on the first 10-hour period only. §Only one 10-hour tape was available on quinidine, which was compared against comparable 10-hour placebo period.
Abbreviations: %t = percentage change calculated as 100 -(100 X PVC rate for drug/PVC rate placebo) for negative changes and (100 X PVC rate for drutg/PVC rate for placebo)-100 for positive changes; PVC = premature ventricular complex. Abbreviations: PVC = premature ventricular complex; Placebo Ph = patients successfully completing trial of phenytoin as described below; Placebo Q = placebo tapes using a 10-hour period for patient 4; Placebo Pr = placebo tapes using 24-hour tape for patient 4. There was a slight increase in the number of couplets and runs with average V-V coupling intervals longer than 600 msec when the patients were taking quinidine.
Quinidine had a marked effect on PVCs with coupling intervals less than 400 msec (p < 0.02). The cumulative distribution of PVCs according to coupling interval ( fig. 2A) shows the reduction in the percentage of PVCs with shorter coupling intervals. Quinidine also reduced the number of PVCs in couplets and runs with V-V coupling intervals of less than 400 msec (p < 0.02, table 5, fig. 2B ). In addition, isolated PVCs with coupling intervals of 400-500 msec and PVCs in couplets and runs with coupling intervals of 400-500 msec were less frequent (p < 0.05).
Discussion
PVCs in any one person may demonstrate different morphologies, coupling intervals and patterns of presentation, such as bigeminy, trigeminy, couplets or runs, presumably reflecting different mechanisms or sites of origin. It would be reasonable to expect that a given antiarrhythmic agent might be very effective in eliminating one or more of the different subgroups but not necessarily all." If the proportion of PVCs comprising these subsets were small relative to the total population of PVCs, an overall effect of the agent might not be seen, even though it might be extremely effective in one subset (see Appendix).
In these patients with coronary artery disease and asymptomatic arrhythmias, quinidine and procainamide preferentially reduced PVCs with short (< 400 msec) coupling intervals either after a normal beat (N-V) (quinidine alone) or another PVC (V-V) (both drugs). This effect could be demonstrated, although an overall reduction in PVC rate did not reach statistical significance in this small patient population. Studies using programmed ventricular stimulation have also demonstrated a prolonged refractory period of the right ventricle in patients given quinidine12 or procainamide,12, 13 a measurable reduction in total PVCs in only a minority of patients.'4 1" However, the very beats that these agents are most effective against, i.e., early beats, and especially the PVCs with short coupling intervals within salvos (short V-V intervals), may be associated with the highest risk of sudden death in patients with heart disease. Both ventricular tachycardia"6 and early PVCs deteriorate into ventricular fibrillation in the setting of acute myocardial ischemia or infarction,5'`6 so eliminating or reducing these PVCs through the use of antiarrhythmics might be expected to reduce the risk of sudden death, even though other PVCs are not affected.
Several The effectiveness of procainamide at the dosage level administered in our trial is somewhat surprising. At the time of the trial, 2 g/day was the standard therapeutic dose. More recently, investigators have suggested that serum levels of [4] [5] [6] [7] [8] ,ug/ml are required for therapeutic effect, so doses of 3-6 g/day are now commonly administered. '9' 20 However, Giardina and Bigger21 demonstrated prolongation of the PVC coupling interval when serum procainamide levels were 2-4 gg/ml. These levels were attained in most of the patients in our study. Ogunkelu et al.22 also reported effects on the refractoriness of the His-Purkinje system at "subtherapeutic" levels of procainamide, an effect that could also be related to suppression of some ventricular arrhythmias.
Studies like this, which use the double-blind crossover design, permit evaluation of the effect of antiarrhythmic agents on the total population of PVCs in the entire group of patients, but evaluation of the response of an individual patient is not possible."' Only one patient who took phenytoin or procainamide showed more than 90% reduction in PVC rates, whereas only four showed such a reduction while taking quinidine. Because of the wide day-to-day variation in PVC rates that may occur,23' 24 less complete reduction in PVC rates cannot be ascribed to drug with the number of recordings used in this study. Similarly, in view of the lack of data on daily variation of coupling-interval-specific PVC rates, no statements regarding response of an individual patient's early PVCs to drugs can be made. The goal of treatment of the patient with asymptomatic ventricular arrhythmia is the prevention of sudden death.6' 17, 25 We have shown that antiarrhythmic agents may act preferentially against forms of ectopy that may be more likely to deteriorate into ventricular fibrillation. Further investigation will be required to determine whether elimination or reduction in the numbers of these more "dangerous" PVCs alone will be associated with prevention of sudden death.
